STAB (Statera BioPharma) Days Sales Outstanding: 0.00 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Days Sales Outstanding?

Statera BioPharma STAB Days Sales Outstanding is 0.00 as of Sep. 2022.

Statera BioPharma's average Accounts Receivable for the three months ended in Sep. 2022 was $0.20 Mil. Statera BioPharma's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

The historical rank and industry rank for Statera BioPharma's Days Sales Outstanding or its related term are showing as below:

STAB's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.98
* Ranked among companies with meaningful Days Sales Outstanding only.

Statera BioPharma's Days Sales Outstanding stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00).

Statera BioPharma  (OTCPK:STAB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Statera BioPharma Days Sales Outstanding Related Terms

Statera BioPharma Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Days Sales Outstanding Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Days Sales Outstanding
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STAB vs NRBO, PALI, BLCM: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Statera BioPharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Days Sales Outstanding falls into.


Statera BioPharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Statera BioPharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

Days Sales Outstanding (A: Dec. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )*Days in Period
=( (0 + 0.216) / 1 ) / 0*365
=0.216 / 0*365
=N/A

Statera BioPharma's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

Days Sales Outstanding (Q: Sep. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2022 ) + Accounts Receivable (A: Sep. 2022 )) / count ) / Revenue (A: Sep. 2022 )*Days in Period
=( (0.218 + 0.183) / 2 ) / 0*365 / 4
=0.2005 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Sales Outstanding →
What does a Days Sales Outstanding of 0.00 mean?
Statera BioPharma (STAB) has a Days Sales Outstanding of 0.00 as of Sep. 2022. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Days Sales Outstanding too high?
Statera BioPharma's current Days Sales Outstanding is 0.00.
How does Statera BioPharma's Days Sales Outstanding compare to NRBO and PALI?
Statera BioPharma's Days Sales Outstanding of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Statera BioPharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Days Sales Outstanding is 0.00 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.